{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:13:43Z","timestamp":1788509623541,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104347","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:59:03Z","timestamp":1779807543000},"page":"104347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, radiolabeling, and biological evaluation of a novel 177Lu-AAZTA5-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9390-9103","authenticated-orcid":false,"given":"Mohamed A.","family":"Gizawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzy A.","family":"Marzook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan M.","family":"El-Shershaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Elrefaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Motaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel A.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-2397","authenticated-orcid":false,"given":"Hesham A.","family":"Shamsel-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104347_bib0001","first-page":"573","article-title":"The genetic and molecular drivers of multiple myeloma: current insights, clinical implications, and the path forward","volume":"17","author":"Ram","year":"2024","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.xphs.2026.104347_bib0002","first-page":"1","article-title":"Diagnosis, risk stratification and management of smouldering multiple myeloma","author":"Zanwar","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.xphs.2026.104347_bib0003","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104347_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.56","article-title":"A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma","volume":"7","author":"Mitra","year":"2017","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.xphs.2026.104347_bib0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13139-017-0505-6","article-title":"Lu-177-based peptide receptor radionuclide therapy for advanced neuroendocrine tumors","volume":"52","author":"Kim","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.xphs.2026.104347_bib0006","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.xphs.2026.104347_bib0007","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1515\/ract-2023-0175","article-title":"Synthesis, in silico and biodistribution studies of a novel 47Sc-radiolabeled \u03b1-amino acid ester derivative attached to pyrazine and tetrazole rings for tumor targeted radiotherapy","volume":"112","author":"Gizawy","year":"2024","journal-title":"Radiochim Acta"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0008","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1874471008666150313114644","article-title":"Theranostic applications of lutetium-177 in radionuclide therapy","volume":"9","author":"Das","year":"2016","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.xphs.2026.104347_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2026.466835","article-title":"A robust gradient chromatographic separation of NCA 177Lu from irradiated natYb target using a DEHPA-impregnated Amberlite resin","volume":"1773","author":"Gizawy","year":"2026","journal-title":"J Chromatogr A"},{"issue":"3","key":"10.1016\/j.xphs.2026.104347_bib0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/156800911794519725","article-title":"Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs)","volume":"11","author":"Kuhn","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.xphs.2026.104347_bib0011","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/fon.11.42","article-title":"Carfilzomib: a novel second-generation proteasome inhibitor","volume":"7","author":"Khan","year":"2011","journal-title":"Fut Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.xphs.2026.104347_bib0014","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/ange.201611207","article-title":"AAZTA: an ideal chelating agent for the development of 44Sc PET imaging agents","volume":"129","author":"Nagy","year":"2017","journal-title":"Angew Chem"},{"key":"10.1016\/j.xphs.2026.104347_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.213908","article-title":"AAZTA: the rise of mesocyclic chelating agents for metal coordination in medicine","volume":"438","author":"Travagin","year":"2021","journal-title":"Coord Chem Rev"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0016","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13550-015-0154-7","article-title":"Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue","volume":"5","author":"Pfister","year":"2015","journal-title":"EJNMMI Res"},{"issue":"2","key":"10.1016\/j.xphs.2026.104347_bib0017","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/ph15020234","article-title":"AAZTA-derived chelators for the design of innovative radiopharmaceuticals with theranostic applications","volume":"15","author":"Fersing","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41181-020-00107-8","article-title":"68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues","volume":"5","author":"Sinnes","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41181-020-00115-8","article-title":"Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist","volume":"5","author":"Hofstetter","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"10.1016\/j.xphs.2026.104347_bib0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02041303","article-title":"Separation of carrier-free lutetium-177 from neutron irradiated natural ytterbium target","volume":"185","author":"Balasubramanian","year":"1994","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.xphs.2026.104347_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2026.112668","article-title":"Evaluation of direct and indirect routes for Lu-177 production at Egyptian Second Research Reactor (ETRR-2)","volume":"234","author":"Gizawy","year":"2026","journal-title":"Appl Radiat Isot"},{"issue":"4","key":"10.1016\/j.xphs.2026.104347_bib0022","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/molecules28041884","article-title":"Radiolysis-associated decrease in radiochemical purity of 177Lu-radiopharmaceuticals and comparison of the effectiveness of selected quenchers against this process","volume":"28","author":"Larenkov","year":"2023","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.xphs.2026.104347_bib0023","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","article-title":"Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities","volume":"30","author":"Breeman","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0024","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41181-023-00191-6","article-title":"Improved quality control of [177Lu] Lu-PSMA I&T","volume":"8","author":"Kraihammer","year":"2023","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.xphs.2026.104347_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113458","article-title":"Cytotoxicity and apoptosis induction by Fumaria officinalis extracts in leukemia and multiple myeloma cell lines","volume":"266","author":"Adham","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.xphs.2026.104347_bib0026","first-page":"1","article-title":"Radiolabeling of protoporphyrin-daratumumab conjugate with 161Tb as a CD38 immunotherapeutic agent for multiple myeloma","author":"Gizawy","year":"2025","journal-title":"J Radioanal Nucl Chem"},{"issue":"2","key":"10.1016\/j.xphs.2026.104347_bib0027","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1021\/acs.jmedchem.2c00733","article-title":"Discovery of highly selective inhibitors of the human constitutive proteasome \u03b25c chymotryptic subunit","volume":"66","author":"Zhan","year":"2023","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0028","doi-asserted-by":"crossref","first-page":"171","DOI":"10.21608\/bfszu.2024.300651.1407","article-title":"Computational chemistry for some novel pyrimidine derivatives as significant antioxidants using cytochrome c peroxidase enzyme","volume":"2025","author":"Shehab","year":"2025","journal-title":"Bull Fac Sci Zagazig Univ"},{"key":"10.1016\/j.xphs.2026.104347_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103971","article-title":"A multifunctional 64+67Cu-pyrazolone complex: green synthesis, radiolabeling, molecular docking, and tumor-targeted theranostic evaluation","volume":"114","author":"Shamsel-Din","year":"2025","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.21608\/bfszu.2024.299799.1403","article-title":"Design, synthesis, and computational studies as cytotoxicity of novel pyrimidine carbonitrile derivatives as dual-target inhibitors of BRD4","volume":"2025","author":"Elsayed","year":"2025","journal-title":"Bull Fac Sci Zagazig Univ"},{"issue":"8","key":"10.1016\/j.xphs.2026.104347_bib0031","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jlcr.3841","article-title":"A novel 99mTc-diester complex as tumor targeting agent: synthesis, radiolabeling, and biological distribution study","volume":"63","author":"Shamsel-Din","year":"2020","journal-title":"J Labell Compd Radiopharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0032","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/psc.2836","article-title":"Advances in Fmoc solid-phase peptide synthesis","volume":"22","author":"Behrendt","year":"2016","journal-title":"J Pept Sci"},{"key":"10.1016\/j.xphs.2026.104347_bib0033","series-title":"Fmoc Solid Phase Peptide Synthesis: A Practical Approach","volume":"222","year":"1999"},{"issue":"3","key":"10.1016\/j.xphs.2026.104347_bib0034","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cbpa.2004.03.002","article-title":"Developments in peptide and amide synthesis","volume":"8","author":"Albericio","year":"2004","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41181-019-0068-1","article-title":"AAZTA5\/AAZTA5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu","volume":"4","author":"Sinnes","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"10.1016\/j.xphs.2026.104347_bib0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874471008666150312160855","article-title":"Production of no-carrier added lutetium-177 by irradiation of enriched ytterbium-176","volume":"8","author":"Tarasov","year":"2015","journal-title":"Curr Radiopharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104347_bib0037","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of 177Lu for targeted radionuclide therapy: available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"16","key":"10.1016\/j.xphs.2026.104347_bib0038","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.xphs.2026.104347_bib0039","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0040","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/10717544.2019.1582730","article-title":"Improving cellular uptake of therapeutic entities through interaction with components of cell membrane","volume":"26","author":"Zhang","year":"2019","journal-title":"Drug Deliv"},{"issue":"26","key":"10.1016\/j.xphs.2026.104347_bib0041","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1200\/JCO.2005.05.012","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma","volume":"23","author":"Lossos","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104347_bib0042","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem Soc Rev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:33:16Z","timestamp":1788507196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001966"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104347","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, radiolabeling, and biological evaluation of a novel 177Lu-AAZTA5-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104347"}}